Rhopressa maintained IOP lowering in patients with glaucoma or ocular hypertension through 12 months in the Rocket 2 phase 3 registration trial, Aerie Pharmaceuticals announced in a press release. Rocket 2 is the second phase 3 registration trial for R…
Multisensory impairment more frequent among African Americans.The first study to measure the full spectrum of age-related damage to all five senses found that 94 percent of older adults in the…
INDIANAPOLIS–(BUSINESS WIRE)–The Finish Line Youth Foundation announced today the award of $77,310 in grants for the fourth quarter of 2015. The 16 grants will help organizations in 13 states that focus on healthy lifestyles, youth development and special needs. In total, the Youth Foundation donated more than $515,500 nationwide with more than $82,200 given to Indianapolis non-profits during 2015. “Thanks to our supporters, we are pleased to have the opportunity to make change happen and emp
Alcon has entered into an agreement to acquire Transcend Medical, Novartis announced in a press release. Transcend Medical has developed a micro-stent to treat mild to moderate glaucoma. The device currently has CE mark approval in Europe and is awaiti…
A study from Lund University in Sweden shows that commonly used chemo toxins impair the eyesight in childhood cancer survivors in a way that indicates an impact on the central nervous system.
BEDFORD, Mass.–(BUSINESS WIRE)–Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced that Amar Sawhney, Ph….